Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

• Status: Completed
• Trial end date: 2017-06-16
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Informed consent obtained before any study-related activities (Study-related activities are any procedure related to recording of data according to the protocol)

• Patients with T2DM (type 2 diabetes mellitus) who the physician has decided to start treatment with Victoza® in combination with insulin or OAD (oral anti-diabetes drug) other than SU (sulfonylurea)

• Male or female, no age limitation

Exclusion Criteria:

• Previous participation in this study or NN2211-3772 Participation is defined as informed consent obtained for this study or enrolment for NN2211-3772

• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

• Patients who are on Victoza® or have previously been on Victoza® within 3 month before the enrolment